Your session is about to expire
← Back to Search
Study Summary
This trial will study DS-9606a to see if it is safe and tolerated in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are expected to live for at least 3 more months.I have ovarian cancer.I am fully active or can carry out light work.I am 18 years old or older.My cancer is advanced or has spread and this was confirmed by a lab test.My organs and bone marrow are functioning well.I agree to give tissue samples before and during treatment, if it's safe for me.Your heart's electrical activity shows a QT interval that is too long based on multiple ECG readings.I have had serious heart issues, including heart failure or irregular heartbeat needing treatment.I have not had a heart attack or unstable chest pain in the last 6 months.My cancer has worsened despite treatment, or I cannot tolerate/choose not to have standard treatment.I have an infection that needs long-term treatment.I agree to use effective birth control or avoid sex during the study and for months after.I had brain metastases but completed treatment over 4 weeks ago with no disease progression and don't need ongoing steroids.My heart pumps well, with an ejection fraction of 50% or higher.You need to have stored tumor samples from previous tests. If you have germ cell tumors without stored samples, you might still be able to join with special permission.My cancer is advanced or has spread, and includes types like ovarian, uterine, pancreatic, lung (non-squamous), or stomach cancer.I have or had lung inflammation that needed steroids, or it might be present but not confirmed.I have an active or uncontrolled hepatitis B or C infection.I haven't had any other cancer besides non-invasive types or those fully treated over 2 years ago.My germ cell tumor has not responded to treatment.
- Group 1: Dose Escalation: DS-9606a
- Group 2: Dose Expansion: Cohort B-1
- Group 3: Dose Expansion: Cohort B-2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does DS-9606a present any potential danger to users?
"The limited amount of available data concerning DS-9606a's efficacy and safety led to our team assigning it a score of 1."
In what locations are the trials for this study taking place?
"Presently, the trial is running in 6 medical centres across the USA, including Detroit, Nashville and Sarasota. To minimize your transportation needs during participation it may be advantageous to select a clinic closest to you."
To what extent has this research enrolled participants?
"Affirmative. According to the clinicaltrials.gov database, this medical trial is actively recruiting participants since it was first posted on May 31st 2022 and recently updated on November 21st 2022. The investigators are targeting 125 patients across 6 distinct sites."
Are individuals currently eligible to join this empirical investigation?
"As seen on clinicaltrials.gov, the trial is actively recruiting participants. It was first advertised on May 31st 2022 and has recently been updated (November 21st 2022)."
Share this study with friends
Copy Link
Messenger